Trump to nominate CEA Chair Miran for Fed governor role
Joseph Douglas Lyon, Chief Accounting & Technology Officer at Corcept Therapeutics (NASDAQ:CORT), sold 5,823 shares of common stock on August 1, 2025, for approximately $393,127. The shares were sold at a weighted average price of $67.5129, with individual sales prices ranging from $67.24 to $67.945.
On the same day, Lyon also exercised options to acquire 5,823 shares of Corcept Therapeutics stock at a price of $13.56 per share, for a total value of $78,959.
Following these transactions, Lyon directly owns 10,066 shares of Corcept Therapeutics, which includes 1,552 shares underlying unvested restricted stock awards.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted on August 30, 2024. Discover more insights about CORT and access 12 additional ProTips with a subscription to InvestingPro, including comprehensive analysis and expert research reports.
In other recent news, Corcept Therapeutics reported its second-quarter 2025 financial results, which included a notable earnings per share (EPS) beat, but a slight shortfall in revenue. The company achieved an EPS of $0.29, surpassing analysts’ expectations of $0.19 by 52.63%. However, the revenue reported was $194.4 million, which was slightly below the anticipated $199.4 million, resulting in a 2.51% surprise. These financial results were accompanied by ongoing supply chain challenges that have been affecting the company. Despite the strong EPS performance, the revenue miss was a point of concern for investors. Analyst firms have yet to release any recent upgrades or downgrades following these results. These developments highlight the mixed financial performance of Corcept Therapeutics in the recent quarter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.